SCHEMBL5246540

SCHEMBL5246540

Cc1cccc(-c2cc(-c3cccc(C)c3)c3nonc3c2)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP4K4 O95819 2/20 0.41
FYN P06241 2/20 0.41
CLK4 Q9HAZ1 2/20 0.41
DYRK1B Q9Y463 2/20 0.41
CHEK1 O14757 1/20 0.41
ABL1 P00519 1/20 0.41
NTRK1 P04629 1/20 0.41
LCK P06239 1/20 0.41
CSF1R P07333 1/20 0.41
MET P08581 1/20 0.41
PDGFRB P09619 1/20 0.41
PIM1 P11309 1/20 0.41
FGFR1 P11362 1/20 0.41
PDGFRA P16234 1/20 0.41
PRKACA P17612 1/20 0.41
LTK P29376 1/20 0.41
GRK5 P34947 1/20 0.41
KDR P35968 1/20 0.41
FLT3 P36888 1/20 0.41
MAPK8 P45983 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4785142 0.84 CHEK1 (0.47) MAP4K4FYNCLK4DYRK1BCHEK1
SCHEMBL4743550 0.83 AKR1C2 (0.43) MAP4K4ENPP3RAB9ANPC1SMN1; SMN2
SCHEMBL5242800 0.82 LMNA (0.35) RAB9ANPC1MEN1MAPK1KMT2A
SCHEMBL5291152 0.81 TDO2 (0.46) MAP4K4FYNCLK4ABL1PDGFRB
SCHEMBL5244253 0.79 MAPT (0.50) RAB9ANPC1SMN1; SMN2HPGDTSHR
SCHEMBL18932997 0.79 APP (0.44) RAB9ANPC1SMN1; SMN2HPGDTSHR
SCHEMBL5245799 0.78 KDM4E (0.41) RAB9ANPC1HPGDMAOBPGR
SCHEMBL4786435 0.72 MAPK1 (0.45) MAP4K4FYNCLK4DYRK1BCHEK1
SCHEMBL18999833 0.72 HTR7 (0.40) LCKKDRRAB9ANPC1SMN1; SMN2
SCHEMBL4255693 0.70 ACHE (0.46) MAP4K4FYNCLK4DYRK1BCHEK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1758873-A1 UBIQUITIN LIGASE INHIBITORS Rigel Pharmaceuticals, Inc. (US) 2007-03-07 EP claimed
WO-2006002284-A1 UBIQUITIN LIGASE INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2006-01-05 WO claimed
US-20050282818-A1 Ubiquitin ligase inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2005-12-22 US claimed
US-20050282818-A1 Ubiquitin ligase inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2005-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050282818-A1 Ubiquitin ligase inhibitors NEDD4, TRAF6, XIAP MAP4K4 2433/4885FYN 647/4885CLK4 3901/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.